{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:13:52Z","timestamp":1762377232338,"version":"3.41.2"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Drug-resistant cytomegalovirus (CMV) infection after hematopoietic stem cell transplantation (HSCT) often leads to morbidity and mortality. Several studies have shown that CMV-cytotoxic T lymphocytes (CTLs) can overcome drug-resistant CMV infection, but still many questions remain unanswered. Here, we present a case of refractory CMV infection after allogeneic HSCT (allo-HSCT). Donor-derived CMV-CTLs failed to eliminate the virus in unique peripheral blood on the first application, when 70 mg methylprednisolone (MP) was taken per day. After a second attempt with a combination of 8 mg MP with leflunomide, a complete and persisting clearance of all involved sites, including peripheral blood, urinary system, leptomeninges, and retina, was achieved. To summarize, intravenous infusion of CTLs can eliminate CMV in the oculi and central nervous system (CNS), and a low dosage of 8 mg MP has no interaction with CMV-CTLs.<\/jats:p>","DOI":"10.3389\/fmed.2022.948210","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T04:52:56Z","timestamp":1662439976000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Donor-derived cytomegalovirus-cytotoxic T lymphocytes and leflunomide successfully control refractory cytomegalovirus infections and disease of multiple sites after allogeneic-hematopoietic stem cell transplantation: A case report"],"prefix":"10.3389","volume":"9","author":[{"given":"Nan","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dali","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1182\/blood.2019000956","article-title":"How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.","volume":"135","author":"Einsele","year":"2020","journal-title":"Blood."},{"key":"B2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jtct.2021.09.010","article-title":"American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation.","volume":"27","author":"Yong","year":"2021","journal-title":"Transplant Cell Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood."},{"key":"B4","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1080\/17843286.2020.1752446","article-title":"Treatment of a patient with severe cytomegalovirus (CMV) infection after haploidentical stem cell transplantation with donor derived CMV specific T cells.","volume":"76","author":"Ingels","year":"2021","journal-title":"Acta Clin Belg."},{"key":"B5","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41409-021-01499-0","article-title":"Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation.","volume":"57","author":"Wang","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.v97.5.1232","article-title":"Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation.","volume":"97","author":"Cwynarski","year":"2001","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1086\/323354","article-title":"Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants.","volume":"184","author":"Aubert","year":"2001","journal-title":"J Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1080\/16078454.2019.1710945","article-title":"Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation.","volume":"25","author":"Ke","year":"2020","journal-title":"Hematology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00277-020-04355-1","article-title":"Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.","volume":"100","author":"Lu","year":"2021","journal-title":"Ann Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/infdis\/jix357","article-title":"Cytomegalovirus-Specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus.","volume":"216","author":"Pei","year":"2017","journal-title":"J Infect Dis."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1900876","article-title":"A simplified CMV-specific T cell transfer targeting drug-resistant CMV retinitis.","author":"Mo","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.oret.2021.04.009","article-title":"Ocular outcomes after treatment of cytomegalovirus retinitis using adoptive immunotherapy with cytomegalovirus-specific cytotoxic T lymphocytes.","volume":"5","author":"Gupta","year":"2021","journal-title":"Ophthalmol Retina."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/631951","article-title":"Improving cytomegalovirus-specific T cell reconstitution after haploidentical stem cell transplantation.","volume":"2014","author":"Luo","year":"2014","journal-title":"J Immunol Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3109\/09273948.2015.1071406","article-title":"Utility of leflunomide in the treatment of drug resistant cytomegalovirus retinitis.","volume":"25","author":"Rifkin","year":"2017","journal-title":"Ocul Immunol Inflamm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1001\/jamaophthalmol.2013.1589","article-title":"Long-term suppression of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide.","volume":"131","author":"Dunn","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3324\/haematol.11912","article-title":"Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.","volume":"93","author":"Lilleri","year":"2008","journal-title":"Haematologica."},{"key":"B17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.bbmt.2018.10.011","article-title":"Cytomegalovirus infection incidence and risk factors across diverse hematopoietic cell transplantation platforms using a standardized monitoring and treatment approach: a comprehensive evaluation from a single institution.","volume":"25","author":"Melendez-Munoz","year":"2019","journal-title":"Biol Blood Marrow Transplant."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.948210\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T04:53:02Z","timestamp":1662439982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.948210\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":17,"alternative-id":["10.3389\/fmed.2022.948210"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.948210","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"article-number":"948210"}}